Search clinical trials for: Enteric coated mycophenolate sodium

Total 12118 results

Zhishui Chen

Not yet recruiting

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Kidney Transplant Rejection
University Hospital, Tours

Not yet recruiting

Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (INSTEAD)

Renal Transplant Rejection | Induction Therapy
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Renal Allograft Recipients

France, United States, Germany, Spain, United Kingdom, Italy, Netherlands, Belgium
National Institute of Allergy and Infectious Diseases...
PPD

Active, not recruiting

Tocilizumab in Cardiac Transplantation

Heart Transplant

United States
University of California, Los Angeles
Novartis

Completed

Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

Liver Transplantation

United States
Cedars-Sinai Medical Center
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (Myfortic®) in Heart Transplant Recipients

Heart Transplantation | Gastrointestinal Symptoms

United States
Novartis

Completed

Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Renal Transplantation | Gastrointestinal Problems

Germany, Switzerland
Ronaldo de Matos Esmeraldo, MD
Novartis Pharmaceuticals

Completed

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Cytomegalovirus Infections | Transplantation Infection

Brazil
Novartis Pharmaceuticals

Completed

A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (MANDELA)

Heart Transplantation

Germany
R. Mark Ghobrial, MD
Novartis

Completed

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

End Stage Liver Disease

United States
University of Pennsylvania
Novartis Pharmaceuticals

Terminated

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Transplants and Implants

United States
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)

Kidney Maintenance Transplant
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Renal Transplant

Korea, Republic of
Novartis Pharmaceuticals

Completed

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (ATHENA)

Kidney Transplantation | Renal Transplantation

Germany, France
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients

Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

Kidney Transplant

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Renal Transplantation

Switzerland
Novartis

Completed

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

Kidney Transplantation
Novartis

Completed

Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients

Renal Transplantation
Novartis

Completed

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

Kidney Transplantation

Switzerland
Novartis

Completed

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Maintenance Kidney Transplant

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients

Kidney Transplantation

United States
Novartis Pharmaceuticals

Completed

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Kidney Transplantation

Germany, Switzerland
Gaetano Ciancio

Completed

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

Transplant; Failure, Kidney

United States
Novartis

Completed

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Liver Transplantation | Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients

Renal Transplant

China
Hospital Universitari Vall d'Hebron Research Institute

Completed

Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations

Systemic Lupus Erythematosus

Spain
East Carolina University
Novartis Pharmaceuticals

Completed

Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)

Transplant; Failure, Kidney

United States
Chulalongkorn University
Clinical Research Collaborative Network; Health Intervention and Technology...

Terminated

The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis (CONTROL)

Lupus Nephritis

Thailand
Novartis Pharmaceuticals

Terminated

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Renal Transplantation

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Chronic Renal Failure

Israel
Novartis Pharmaceuticals

Completed

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Renal Function

Denmark, Norway, Sweden
Novartis

Completed

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Renal Transplantation

Switzerland, Germany
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Kidney de Novo Transplant
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients

Heart Transplantation

United States, Australia, Argentina, Canada
Novartis Pharmaceuticals

Completed

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Kidney Transplant Recipients
Novartis Pharmaceuticals

Terminated

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

De Novo Kidney Transplant
Novartis Pharmaceuticals

Completed

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107

Renal Transplant
Novartis Pharmaceuticals

Completed

A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)

Renal Transplantation
Novartis Pharmaceuticals

Completed

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

Renal Transplantation
Armin Goralczyk

Unknown

Safety Study of Calcineurin-Inhibitor-Free Immunosuppression After Liver Transplantation (CILT)

Liver Transplantation | Chronic Renal Insufficiency

Germany
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Renal Transplantation

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

Lupus Nephritis

France, Spain, Colombia, Hungary, Italy, Germany, Greece, Taiwan, United Kingdom
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

Kidney Transplantation | Pancreas Transplantation

Germany
Novartis

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients (OLYMPE)

Kidney Diseases

Switzerland
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

Autoimmune Disease

Germany
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients

Renal Transplantation

France

3

Subscribe